IL-28B reduced the frequency of splenic CD4+Foxp3+ cells in H22 tumor-bearing mice and the percentage of Foxp3+ cells after adding IL-28B at 5, 50, or 400 ng/ml. Here, IFNL3 is linked to neoplasm.